Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses Armored RNA Technology to Cepheid for Diagnostic Assays

NEW YORK, April 11 (GenomeWeb News) - Cepheid has licensed technology for RNA standards and controls from Ambion Diagnostics for use in molecular diagnostic assays, Ambion said today.


Under the agreement, Cepheid gets non-exclusive rights to incorporate Ambion's Armored RNA technology into in vitro diagnostics. Ambion Diagnostics, a division of Ambion, will manufacture custom reagents for Cepheid, which will use them with its SmartCycler and GeneXpert platforms.


Armored RNA technology, invented by Ambion and Cenetron, helps to stabilize RNA by packaging it in bacteriophage coat proteins. A major application is the production of RNA controls and standards for viral assays. Cepheid plans to use the technology to develop diagnostic tests in the areas of infectious diseases and oncology.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.